Quintrio
Home

PHARMACEUTICAL PREPARATIONS

Shattuck Labs, Inc. Common Stock

STTK

Shattuck Labs Inc is a biotechnology company specializing in the development of potential treatments for inflammatory and immune-mediated diseases. It is developing a potentially first-in-class antibody for the treatment of inflammatory bowel disease (IBD) and other inflammatory and immune-mediated diseases. The company's expertise in protein engineering and the development of novel tumor necrosis factor (TNF) receptor therapeutics comes together in its main program, SL-325, which has the potential to be a first-in-class death receptor 3 (DR3) antagonist antibody. In addition, the company is developing SL-425, a half-life extended version of SL-325, and multiple other preclinical DR3-based bispecific antibodies, for the treatment of patients with IBD.

Last trade $4.52
Day change -$0.14 (-3.00%)
Day range $4.08 – $4.76
Volume 346,746
Market cap $475M

Open XNAS

Fundamentals

Key company ratios and reported financial statements.

Source: Massive.com

Key ratios

Valuation

Market capitalization
$474.59M
Price / earnings
—
Price / book
2.45×
Price / sales
—
EV / sales
—
EV / EBITDA
-6.01×

Profitability

Earnings per share
-$0.66
Return on assets
-32.56%
Return on equity
-34.97%
Dividend yield
0%

Liquidity and leverage

Debt / equity
0×
Current ratio
15.8×
Quick ratio
15.8×
Cash ratio
4.84×

Cash flow

Price / cash flow
—
Price / free cash flow
—
Free cash flow
-$49.76M

Ratios use trailing-twelve-month financials and market data as of Nov 16, 2026.

Financial statements

Income and cash flow amounts are for the period; balance sheets are point-in-time snapshots. Amounts are shown in USD. Latest 8 quarterly or 5 annual periods are displayed when available.

Income statement for STTK, quarterly periods
Line itemQ3 FY2026 Sep 30, 2026Q2 FY2026 Jun 30, 2026Q1 FY2026 Mar 31, 2026Q4 FY2025 Dec 31, 2025Q3 FY2025 Sep 30, 2025Q2 FY2025 Jun 30, 2025Q1 FY2025 Mar 31, 2025Q4 FY2024 Dec 31, 2024
Revenue$0$0$0$0$1M$0$0$0
Cost of revenue$0$0$0$0$0$0$0$0
Gross profit$0$0$0$0$1M$0$0$0
Selling, general and administrative$5.48M$4.46M$4.6M$4.32M$4.1M$4.35M$4.47M$4.25M
Research and development$21.57M$11.7M$10.95M$9.06M$7.62M$8.68M$9.92M$15.4M
Total operating expenses$27.05M$16.16M$15.55M$13.37M$11.72M$13.03M$14.39M$19.64M
Operating income-$27.05M-$16.16M-$15.55M-$13.37M-$10.72M-$13.03M-$14.39M-$19.64M
Interest expense$0$0$0$0$0$0$0$0
Income before taxes-$25.2M-$15.15M-$14.77M-$12.59M-$10.06M-$12.46M-$13.7M-$18.68M
Income taxes$0$0$0$0$0$0$0$0
Net income-$25.2M-$15.15M-$14.77M-$12.59M-$10.06M-$12.46M-$13.7M-$18.68M
Net income attributable to common shareholders-$25.2M-$15.15M-$14.77M-$12.59M-$10.06M-$12.46M-$13.7M-$18.68M
EBITDA-$26.23M-$15.3M-$14.65M-$12.47M-$9.8M-$12.1M-$13.45M-$18.7M
Basic earnings per share-$0.14-$0.12-$0.13-$0.12-$0.14-$0.24-$0.27-$0.37
Diluted earnings per share-$0.14-$0.12-$0.13-$0.12-$0.14-$0.24-$0.27-$0.37

Recent news

Company coverage with links to the original publishers.

Publication times in UTC
Zacks Investment Research

Denali Therapeutics Inc. (DNLI) Reports Q3 Loss, Beats Revenue Estimates

Denali Therapeutics reported a Q3 loss of $0.64 per share, beating consensus estimates of $0.69 loss, with an earnings surprise of +7.25%. The company posted revenues of $17.78 million, surpassing revenue estimates by 41.88% compared to zero revenues a year ago. The stock has gained 14.2% year-to-date, outperforming the S&P 500's 10.2% gain. Denali holds a Zacks Rank #3 (Hold) rating with mixed estimate revisions.

The Motley Fool

What Shattuck Labs Stock Topped the Market on Monday

Shattuck Labs (STTK) gained nearly 5% on Monday following positive analyst coverage from two firms. TD Cowen initiated a buy rating while Raymond James issued a strong buy with an $18 price target (more than double the $7.90 closing price). The optimism centers on the company's lead drug candidate SL-325, a first-in-class autoimmune and inflammatory disease treatment currently in Phase 2b clinical testing for inflammatory bowel disease, with analysts estimating a $20+ billion addressable market.

The Motley Fool

Why Shattuck Labs Stock Flew Nearly 5% Higher on Friday

Shattuck Labs stock rose nearly 5% on Friday following JPMorgan Chase analyst Brian Cheng's initiation of coverage with an 'overweight' rating and $10 price target (35% upside). The bullish call was driven by positive clinical trial data for the company's lead drug candidate SL-325, a first-in-class antagonist antibody for inflammatory bowel disease, which showed a cleaner safety profile and stronger target engagement than competitors. The drug is scheduled to enter Phase 2 trials in Q3.

Benzinga

Shattuck Labs, Inc. Announces Pricing of $75 Million Public Offering

Shattuck Labs (NASDAQ: STTK), a clinical-stage biotechnology company, announced the pricing of a $75 million public offering consisting of 10.88 million shares at $4.00 per share and 7.87 million pre-funded warrants at $3.9999 per warrant. The offering is expected to close on June 11, 2026, with underwriters including Leerink Partners, J.P. Morgan, Piper Sandler, and Cantor.

GlobeNewswire Inc.

Shattuck Labs, Inc. Announces Pricing of $75 Million Public Offering

Shattuck Labs, a clinical-stage biotechnology company developing DR3 blocking antibodies, announced the pricing of a public offering of 10.9 million shares at $4.00 per share and 7.9 million pre-funded warrants at $3.9999 per warrant, expected to raise approximately $75 million gross proceeds. The offering is expected to close on June 11, 2026, with Leerink Partners, J.P. Morgan, Piper Sandler, and Cantor serving as joint bookrunning managers.

Dividends

Declared distributions and recorded event dates. Forecasts are not shown.

Updated daily

No declared upcoming dividend found.

No prior dividend records found.

Stock splits

Historical share-structure events and their execution dates.

Updated daily
Execution dateSplit ratioEvent type
Dec 6, 20161-for-800reverse split
Mar 31, 20091-for-250reverse split